drugset / Trial / NCT04626739
CAR-T Cells in Treating Patients With Relapsed or Refractory NHL
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Subject | CD19+CD22 CAR-T | Cell therapy | — | — |
| Subject | CD22 CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |